Kinshasa, October 26 (QNA) — Health authorities in the Democratic Republic of the Congo have announced the launch of an Ebola vaccine trial, a move aimed at supporting health efforts to curb the spread of the disease.

The vaccine trials involve evaluating safety and efficacy, identifying target groups for vaccination, and monitoring for any potential side effects throughout the various stages of research.

Experts have emphasized that the start of the trial does not imply that the vaccine has been approved for general use or that its final efficacy has been established; rather, the results will depend on data collected and analyzed during the clinical study phases.

Health authorities in the Congo continue to rely on measures such as case surveillance, isolation of infected individuals, contact tracing, and public health awareness campaigns—all of which are fundamental pillars for limiting the transmission of the virus—in addition to providing necessary equipment for frontline health workers.

In mid-May, the Democratic Republic of the Congo announced an outbreak of Ebola, a highly lethal disease that has claimed the lives of more than 15,000 people in Africa over the past 50 years. (QNA)